NEW YORK--(BUSINESS WIRE)--PIN Pharma, a pre-clinical immunotherapy company focused on modulating the immune system in oncology, today announced the Company will be presenting PIN-2: A Novel “Immunopriming” Polypeptide Initiates a Peripheral Systemic Innate and Adaptive Immune Response in an Aggressive 4T1 Murine Mammary Carcinoma Model in São Paulo, Brazil on Saturday, May 6, 2017 from 1:00 p.m. – 3:00 p.m.
About PIN Pharma, Inc.
PIN Pharma is a pre-clinical stage venture backed immunotherapy company focused on the development of PINS (precision immune stimulants). The lead compound PIN-2 is a first-in-class, novel, next-generation engineered peptide that empowers the immune system in vivo. The Company’s technology primes the innate immune system to modulate adaptive immunity thereby generating and expanding antigen-specific cytotoxic T-cells in vivo. The company is advancing PIN-2 to the clinic early first quarter 2017.
For more information about PIN Pharma and PIN-2, contact Mark Smith, CFO (firstname.lastname@example.org) or Colin Bier, CEO (email@example.com) at PIN Pharma, Inc., 3960 Broadway, Suite 620, New York, NY, or call 212-543-2583.